Baseline demographics and disease characteristics in the SELECT-PsA 1, SELECT-PsA 2 and SELECT-AXIS 1 studies
| SELECT-PsA 1 | SELECT-PsA 2 | SELECT-AXIS 1 | |||||
| PBO-to-UPA 15 mg once daily (n=211) | UPA 15 mg once daily (n=429) | ADA 40 mg every other week (n=429) | PBO-to-UPA 15 mg once daily (n=106) | UPA 15 mg once daily (n=211) | PBO-to-UPA 15 mg once daily (n=94) | UPA 15 mg once daily (n=93) | |
| Men, n (%) | 113 (53.6) | 191 (44.5) | 207 (48.3) | 49 (46.2) | 98 (46.4) | 69 (73.4) | 63 (67.7) |
| Age, year | 50.0 (12.3) | 51.6 (12.2) | 51.4 (12.0) | 52.3 (11.7) | 53.0 (12.0) | 43.7 (12.1) | 47.0 (12.8) |
| White race, n (%) | 190 (90.0) | 386 (90.0) | 375 (87.4) | 91 (85.8) | 183 (86.7) | 76 (80.9) | 79 (84.9) |
| Time since diagnosis, year | 6.4 (7.4) | 6.2 (7.4) | 5.9 (7.1) | 10.3 (10.0) | 9.6 (8.4) | 6.0 (6.8) | 7.8 (10.6) |
| SPARCC SIJ | — | — | — | — | — | 5.4 (8.6) n=80 | 7.8 (10.9) n=85 |
| SPARCC spine | — | — | — | — | — | 11.9 (14.5) n=81 | 10.5 (14.3) n=85 |
| TJC68 | 20.7 (15.7) | 20.4 (14.7) | 20.1 (13.8) | 26.1 (18.0) | 24.9 (17.3) | 3.5 (6.5) | 4.3 (8.1) |
| SJC66 | 11.4 (8.5) | 11.6 (9.3) | 11.6 (8.8) | 11.8 (9.0) | 11.3 (8.2) | 1.0 (2.3) | 1.1 (3.3) |
| Patient’s global assessment of pain (0–10 NRS) | 6.0 (2.2) | 6.2 (2.1) n=425 | 6.0 (2.1) n=428 | 6.6 (2.1) n=105 | 6.4 (2.1) n=208 | 6.9 (1.6) | 6.8 (1.6) n=91 |
| Patient’s assessment of back pain (0–10 NRS) | — | — | — | — | — | 6.7 (1.8) | 6.8 (1.8) |
| Patient’s assessment of nocturnal back pain (0–10 NRS) | — | — | — | — | — | 6.3 (2.0) | 6.4 (2.3) n=91 |
| BASDAI | 5.8 (1.8) n=73* | 5.9 (2.0) n=138* | 5.7 (2.2) n=125* | 6.6 (1.9) n=39* | 5.9 (2.1) n=75* | 6.5 (1.6) | 6.3 (1.8) n=92 |
| BASDAI Q2 (NRS 0–10) | 5.0 (3.2) | 5.1 (3.1) n=423 | 4.9 (3.0) n=427 | 6.1 (2.8) n=104 | 5.8 (3.1) n=208 | 7.3 (1.5) | 7.1 (1.8) n=92 |
| BASDAI Q3 (NRS 0–10) | 5.9 (2.5) | 6.1 (2.5) n=423 | 5.9 (2.6) n=427 | 6.5 (2.3) n=104 | 6.1 (2.4) n=208 | 5.9 (2.4) | 5.6 (2.3) n=92 |
| SF-36 bodily pain domain | 36.6 (7.2) | 35.7 (7.1) n=425 | 36.7 (7.2) n=428 | 35.0 (7.6) n=105 | 35.9 (7.2) n=208 | — | — |
| SF-36 mental component summary | 45.6 (11.6) | 44.7 (11.7) n=425 | 45.0 (11.0) n=428 | 43.3 (12.1) n=105 | 44.7 (11.2) n=208 | — | — |
Data are mean (SD) unless otherwise noted.
*Assessed only in patients with presence of psoriatic spondylitis.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; NRS, numeric rating scale; PBO, placebo; SF-36, 36-item Short Form; SJC, swollen joint count; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada; TJC, tender joint count; UPA, upadacitinib.